Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaluritamig in Metastatic Castration-resistant Prostate Cancer
NCT07493512Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Apr 2026
- Primary completion
- Jul 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of xaluritamig in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Amgen. Primary endpoint: Number of Participants with Treatment-emergent Adverse Events up to 3.6 Year. Started Apr 2026; status: recruiting.
02
Drugs
xaluritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07493512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493512.